See what’s new.
NSF-Piedmont Triad Regenerative Medicine Engine (PTRME) Awards $2.5 Million in Grants to Drive Economic Growth
BMI OrganBank licensed perfusion tech from the Duke Ex-Vivo Organ Lab, led by Drs. Andrew S. Barbas and Matthew Hartwig (Surgery, SOM).
Invented at Duke 2024 showcases the past and present of innovation at Duke, promising a bright future
A special Centennial edition of Invented at Duke featured inventors and innovations from the past, present, and future of Duke.
BMI OrganBank Secures $3.5 Million NIH Grant to Advance Innovative Kidney Preservation Technology Towards Clinical Trials
BMI OrganBank licensed perfusion tech from the Duke Ex-Vivo Organ Lab, led by Drs. Andrew S. Barbas and Matthew Hartwig (Surgery, SOM).
DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform to Characterize Drug Effects and Optimize Neurological Care
DANNCE.ai, a start-up from the lab of Assistant Professor Timothy Dunn (BME, Pratt), is also in the Duke Capital Partners portfolio.
Soundwaves That Shed New Light
An imaging technology 'listens' to the sound of light to study different biological phenomena. The Yao lab is an inventor booth at Invented at Duke 2024.
Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B
Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).
Injecting Hope
Researchers say injectable gel-like substance has healing powers for bone injuries. OsteoCure is an inventor booth at Invented at Duke 2024.
Early-stage startups meet potential investors, partners at Triangle Venture Day
A total of 20 Triangle startups – including 4 with Duke roots – pitched their ideas to an audience that included more than 50 investor and strategic partnership groups at the Raleigh Convention Center.
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Uplizna, an antibody therapy for immune diseases, is based on technology licensed from Duke University, developed by the late Dr. Thomas Tedder (Immunology, SOM) and colleagues.